Last Updated: November 8, 2026

PEXEVA Drug Patent Profile

« Back to Dashboard


When do Pexeva patents expire, and when can generic versions of Pexeva launch?

Pexeva is a drug marketed by Sebela Ireland Ltd and is included in one NDA.

The generic ingredient in PEXEVA is paroxetine mesylate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Pexeva

A generic version of PEXEVA was approved as paroxetine mesylate by ACTAVIS LABS FL INC on June 20th, 2017.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for PEXEVA?
  • What are the global sales for PEXEVA?
  • What is Average Wholesale Price for PEXEVA?
Recent Clinical Trials for PEXEVA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sheppard Pratt Health SystemN/A
Central Michigan UniversityN/A

See all PEXEVA clinical trials

US Patents and Regulatory Information for PEXEVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-001 Jul 3, 2003 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-004 Jul 3, 2003 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-002 Jul 3, 2003 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sebela Ireland Ltd PEXEVA paroxetine mesylate TABLET;ORAL 021299-003 Jul 3, 2003 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PEXEVA

International Patents for PEXEVA

See the table below for patents covering PEXEVA around the world.

Country Patent Number Title Estimated Expiration
Austria 200781 ⤷  Start Trial
Australia 3108097 ⤷  Start Trial
Bulgaria 103980 ⤷  Start Trial
Bulgaria 64315 ⤷  Start Trial
Brazil 9714787 ⤷  Start Trial
Canada 2293247 COMPOSES 4-PHENYLPIPERIDINE (4-PHENYLPIPERIDINE COMPOUNDS) ⤷  Start Trial
Czech Republic 295301 Deriváty 4-fenylpiperidinu, způsob jejich přípravy, jejich použití a lék je obsahující (4-Phenylpiperidine derivatives, process of their preparation, their use and medicament in which the derivatives are comprised) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.